Additionally, they found that higher dosages of testosteronelead to more growth inhibition of relapsed tumors suggesting that the manipulation ofandrogen/AR signaling pathway may be a potential therapeutic target in AR-positivemetastatic prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.